{'fraction_non_alphanumeric': 0.01498751040799334, 'fraction_numerical': 0.00749375520399667, 'mean_word_length': 5.164102564102564, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Treatment of asthmatic patients with zafirlukast].

BACKGROUND
Asthma is a chronic inflammatory illness of the airways in which several cells intervene playing an important role in the development of the bronchial hyperreactivity. Leukotriens are mediators that participate in the inflammatory process.


OBJECTIVES
To value the effectiveness of the zafirlukast in patients with persistent moderate and severe asthma, and to investigate the undesirable effects and the symptoms of intolerance in the study group.


PATIENTS AND METHODS
The study was carried out on 103 moderate and severe persistent asthmatic patients, with ages between 15 and 50 years, without antecedents of haematological, hepatic or renal diseases, who received 20 milligrams of zafirlukast twice daily during one year. The monitoring was done every month based on its clinical evolution, with control of the renal and hepatic function at the beginning, at six months and at the end of the study. Tests of respiratory function were made at the beginning and the end of the treatment.


CONCLUSIONS
The results show the effectiveness of this medicine, without problems of intolerance or other important secondary adverse effects.